Abstract: A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized backbone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having biomedical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents.

Abstract: A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized backbone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having biomedical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents.

Abstract: A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized back-bone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having bio-medical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized back-bone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having bio-medical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.

Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.

Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carbo

Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carbo

Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.

Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

Abstract: The present invention relates to Trichoderma atroviride strains and their use as biological control agents or plant growth promoters. Methods and compositions for biological control of soil borne plant pathogens, and increasing plant yield using T. atroviride are also provided.

Abstract: The present invention relates to Trichoderma atroviride strains and their use as biological control agents or plant growth promoters. Methods and compositions for biological control of soil borne plant pathogens, and increasing plant yield using T. atroviride are also provided.